Compare TNYA & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNYA | III |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | 1500 |
| Industry | Medicinal Chemicals and Botanical Products | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 203.8M |
| IPO Year | 2021 | 2006 |
| Metric | TNYA | III |
|---|---|---|
| Price | $0.86 | $4.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.33 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 4.7M | 239.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | 54.96 | ★ 216.67 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $192,745,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | N/A | $4.34 |
| P/E Ratio | ★ N/A | $90.70 |
| Revenue Growth | N/A | ★ 4.51 |
| 52 Week Low | $0.44 | $3.74 |
| 52 Week High | $2.35 | $6.45 |
| Indicator | TNYA | III |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 63.70 |
| Support Level | $0.65 | $4.44 |
| Resistance Level | $0.94 | $6.06 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 28.75 | 88.97 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.